254 related articles for article (PubMed ID: 35406796)
1. Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.
Niessner H; Burkard M; Leischner C; Renner O; Plöger S; Meraz-Torres F; Böcker M; Hirn C; Lauer UM; Venturelli S; Busch C; Sinnberg T
Cells; 2022 Apr; 11(7):. PubMed ID: 35406796
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
Carroll MJ; Parent CR; Page D; Kreeger PK
BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
5. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
[TBL] [Abstract][Full Text] [Related]
6.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
7. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
8. M-CSF as a therapeutic target in BRAF
Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
[TBL] [Abstract][Full Text] [Related]
9. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
10. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
[TBL] [Abstract][Full Text] [Related]
11. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.
Bokharaie H; Kolch W; Krstic A
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883549
[TBL] [Abstract][Full Text] [Related]
13. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
15. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
16. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
[TBL] [Abstract][Full Text] [Related]
18. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
19. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
[TBL] [Abstract][Full Text] [Related]
20. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
